<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor VIII, recombinant porcine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor VIII, recombinant porcine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor VIII, recombinant porcine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="98365" href="/d/html/98365.html" rel="external">see "Factor VIII, recombinant porcine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26452644"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Obizur</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871834"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Obizur</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26320030"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihemophilic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F26448329"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b929444-ff6e-4ee5-9e45-d93334c0db10">Acquired hemophilia A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acquired hemophilia A:</b>
<b>IV:</b>
<b>Note:</b> Dose, dosing frequency, and duration based on location and severity of bleeding, target factor VIII levels, and clinical condition of the patient. Plasma levels of factor VIII should not exceed 200% of normal or 200 units/dL. Patients with inhibitory antibodies to recombinant porcine factor VIII may require higher doses and/or more frequent administration than patients without inhibitory antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25623166']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25623166'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Minor to moderate hemorrhage:</i> 200 units/kg initially to achieve factor VIII plasma level 50% to 100% of normal; titrate subsequent doses to maintain recommended factor VIII trough levels and individual clinical response; dose every 4 to 12 hours (frequency may be adjusted based on clinical response/factor VIII levels).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Major hemorrhage:</i> 200 units/kg initially to achieve factor VIII plasma level 100% to 200% (for acute bleed) or 50% to 100% (after acute bleed is controlled, if required) of normal; titrate subsequent doses to maintain recommended factor VIII trough levels and individual clinical response; dose every 4 to 12 hours (frequency may be adjusted based on clinical response/factor VIII levels).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-</i>
<i>label dosing:</i> Based on limited data: 100 units/kg initially; titrate subsequent doses and dosing interval to maintain targeted peak and trough levels based on individual clinical response; refer to protocols for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27704655','lexi-content-ref-27480782','lexi-content-ref-27511890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27704655','lexi-content-ref-27480782','lexi-content-ref-27511890'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0283abf2-3154-49da-a36b-a89ec6b507f7">Congenital hemophilia A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital hemophilia A (off-label use):</b> Based on limited data: <b>IV:</b> Initial: 200 units/kg; titrate subsequent doses based on factor VIII activity levels and individual clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27761964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27761964'])">Ref</a></span>). <b>Note:</b> Loading doses used in this protocol varied based on the level of porcine factor VIII inhibitor levels (refer to protocol for further details); however, the authors concluded that a 200 units/kg loading dose is more clinically feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27761964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27761964'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990320"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987659"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F54316834"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">There are insufficient data to recommend the best dosing weight to use in patients with obesity. Dose adjustments should ultimately be made based on individual patient response to therapy. Due to the paucity of data, refer to institutional protocols. Refer to adult dosing for indication-specific dosing.</p></div>
<div class="block doe drugH1Div" id="F26448330"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F26452671"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased factor VIII inhibitors (anamnestic reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p></div>
<div class="block coi drugH1Div" id="F26320033"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Life-threatening hypersensitivity reactions to antihemophilic factor (recombinant [porcine sequence]) or any component of the formulation (including traces of hamster proteins); congenital hemophilia A with inhibitors due to high incidence of anamnestic reactions to human factor VIII and porcine factor VIII.</p></div>
<div class="block war drugH1Div" id="F26448321"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:0em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Formation of antiporcine factor VIII antibodies has occurred; monitor patients for the development of antibodies. Suspect an antiporcine factor VIII antibody if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration. Anamnestic reactions with rise in human factor VIII inhibitors and/or recombinant factor VIII, porcine sequence inhibitors have been reported and may result in a lack of response to antihemophilic factor. If inhibitory antibodies are suspected and there is a lack of clinical response, consider other therapy (eg, factor VIII bypassing agent).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions may occur; discontinue immediately if allergic or anaphylactic-type reactions occur.</p>
<p style="text-indent:0em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hamster protein: May contain trace amounts of hamster proteins.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sucrose: May contain sucrose.</p>
<p style="text-indent:0em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.</p></div>
<div class="block dosfc drugH1Div" id="F50640545"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Strength expressed with approximate value. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F26523976"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Obizur: 500 units (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F26523975"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52871835"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 units (1 ea)</p></div>
<div class="block adm drugH1Div" id="F26448334"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer IV at a rate of 1 to 2 mL/minute. Do not administer in the same tubing or container with other medications.</p></div>
<div class="block use drugH1Div" id="F26320032"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acquired hemophilia A:</b> On-demand treatment and control of bleeding episodes in adults with acquired hemophilia A.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for the treatment of von Willebrand disease; safety and efficacy have not been established in patients with baseline anti- porcine factor VIII inhibitor titer &gt;20 BU.</p></div>
<div class="block off-label drugH1Div" id="F53273181"><span class="drugH1">Use: Off-Label: Adult</span><p>Congenital hemophilia A</p></div>
<div class="block mst drugH1Div" id="F26448314"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor VIII may be confused with Factor XIII</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Confusion may occur due to the omitting of “Factor VIII” from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F26432516"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F26432513"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F26448318"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregnant carriers of hemophilia A may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor VIII levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor VIII concentrations increase in pregnant patients, factor VIII replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor VIII concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If replacement with a factor VIII concentrate product is indicated, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block brc drugH1Div" id="F26448320"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if antihemophilic factor is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F26448336"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate and BP (before and during IV administration); plasma factor VIII activity prior to and during treatment (30 minutes and 3 hours after initial dose; 30 minutes after subsequent doses); development of factor VIII inhibitors or presence of cross-reacting antibodies prior to treatment if clinically indicated and during treatment if expected plasma factor VIII activity levels are not attained or if bleeding is not controlled as expected (manufacturer recommends using the Nijmegen Bethesda inhibitor assay with recombinant porcine factor VIII as substrate for recombinant porcine factor VIII antibodies); signs of bleeding; hemoglobin, hematocrit.</p></div>
<div class="block rer drugH1Div" id="F26448327"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Classification of hemophilia; normal is defined as 100% factor VIII (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Mild: Factor level &gt;5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F26448325"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Factor VIII replacement, necessary for clot formation and maintenance of hemostasis, activates factor X in conjunction with activated factor IX. Activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939889"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Obizur</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23645693">
<a name="23645693"></a>Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. <i>Haematologica</i>. 2013;98(9):1481-1486. doi:10.3324/haematol.2013.084038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/23645693/pubmed" id="23645693" target="_blank">23645693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25623166">
<a name="25623166"></a>Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. <i>Haemophilia</i>. 2015;21(2):162-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/25623166/pubmed" id="25623166" target="_blank">25623166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27761964">
<a name="27761964"></a>Mahlangu JN, Andreeva TA, Macfarlane DE, Walsh C, Key NS. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. <i>Haemophilia</i>. 2017;23(1):33-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/27761964/pubmed" id="27761964" target="_blank">27761964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27704655">
<a name="27704655"></a>Martin K, Kasthuri R, Mooberry MJ, Chen SL, Key NS, Ma AD. Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy. <i>Haemophilia</i>. 2016;22(6):e549-e551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/27704655/pubmed" id="27704655" target="_blank">27704655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29039750">
<a name="29039750"></a>McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis. <i>Pharmaceutics</i>. 2017;9(4):47. doi:10.3390/pharmaceutics9040047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/29039750/pubmed" id="29039750" target="_blank">29039750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHF.1">
<a name="NHF.1"></a>National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed January 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Obizur.1">
<a name="Obizur.1"></a>Obizur (antihemophilic factor [recombinant (porcine sequence)]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi:10.1111/1471-0528.14592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22776238">
<a name="22776238"></a>Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-e47. doi:10.1111/j.1365-2516.2012.02909.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/22776238/pubmed" id="22776238" target="_blank">22776238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27480782">
<a name="27480782"></a>Stemberger M, Möhnle P, Tschöp J, Ney L, Spannagl M, Reincke M. Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy. <i>Haemophilia</i>. 2016;22(5):e472-e474.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/27480782/pubmed" id="27480782" target="_blank">27480782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27511890">
<a name="27511890"></a>Tarantino MD, Cuker A, Hardesty B, Roberts JC, Sholzberg M. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. <i>Haemophilia</i>. 2017;23(1):25-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/27511890/pubmed" id="27511890" target="_blank">27511890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31887776">
<a name="31887776"></a>Tiede A, Cid AR, Goldmann G, et al. Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A. <i>Thromb Haemost</i>. 2020;120(2):277-288. doi:10.1055/s-0039-3400745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-porcine-drug-information/abstract-text/31887776/pubmed" id="31887776" target="_blank">31887776</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 97772 Version 85.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
